Lung Diseases Cies Search Engine [selected websites]

Loading

Blog Archive

Apr 25, 2008

Kosan : Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer

April 14, 2008 - Kosan Biosciences Incorporated (Nasdaq: KOSN) announced that the Phase 2 trial of epothilone KOS-1584 in patients with non-small cell lung cancer has been initiated. The Phase 2 trial is an open-label, multi-center, monotherapy study of KOS-1584 in patients with measurable advanced or metastatic non-small cell lung cancer who have previously received only one prior chemotherapy regimen. The primary endpoint of the Phase 2 trial is objective response rate. Secondary endpoints include progression-free survival, time to progression, time to treatment failure, time to response, duration of response and overall survival. KOS-1584 will be administered via a 3-hour intravenous infusion weekly for two weeks out of every three weeks at a dose of 25 mg/m(2). The Phase 2 trial will enroll up to 50 patients in a two-stage Simon design... Kosan Biosciences' Press Release -